Anixa Biosciences, Inc.

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. Anixa's…More vaccine portfolio consists of a technology focused on the immunization against a "retired" protein, α-Lactalbumin, to prevent triple negative breast cancer (TNBC), the most lethal form of breast cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.